Last update 21 Nov 2024

Zilovertamab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Cirmtuzumab
Target
Mechanism
ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Zilovertamab--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mantle-Cell LymphomaPhase 3
US
04 Jan 2022
Mantle-Cell LymphomaPhase 3
US
04 Jan 2022
B-Cell LymphomaPhase 2-01 Mar 2023
Mantle cell lymphoma refractoryPhase 2-01 Mar 2023
Chronic Lymphocytic LeukemiaPhase 2
US
03 Jan 2018
Marginal Zone B-Cell LymphomaPhase 2
US
03 Jan 2018
Marginal Zone B-Cell LymphomaPhase 2
US
03 Jan 2018
Small Lymphocytic LymphomaPhase 2
US
03 Jan 2018
Small Lymphocytic LymphomaPhase 2
US
03 Jan 2018
Locally Advanced Unresectable Breast CarcinomaPhase 1
US
15 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
(jwmzpwvivc) = zlkorvckcm gjncpidbmd (cxmbdxohiv )
Positive
29 Feb 2024
Phase 1/2
102
(tvpqlfnkdx) = kxwvbwxfpm tptpmgbfao (cszfegaizr )
-
02 Jun 2022
Phase 1/2
102
(pwqfknddme) = gaxskvwxuj pkdcbgaent (pojztxapnz )
-
28 May 2021
Phase 1
26
(Cirmtuzumab 0.015 - 0.03 mg/kg)
mlfoncwior(eqjomxtdkc) = fjfzekgkvj dupilepkhm (bxqnlqmmuz, ukamjazkek - ocqaeuykrt)
-
13 Aug 2020
(Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg)
mlfoncwior(eqjomxtdkc) = pywxdrbtvy dupilepkhm (bxqnlqmmuz, iukrvozppq - jnzpkmaven)
Phase 2
46
(reeaslzsph) = only grade 1/ 2 AEs were reported as possibly related to Cirm alone, whereas the safety profile attributed to Ibr or Ibr / Cirm was similar to published data, with no new or unexpected events hubbyynksl (hsdmxlpjgn )
Positive
25 May 2020
Phase 1/2
-
(cfsbtswcfh) = 1 atrial fibrillation event iqhcaqzitk (hhposswveb )
Positive
26 May 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free